+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 2Years - 18Years
All Genders
ID06284577

Probiotics and Quality of Life in Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Treatment

Led by Oslo University Hospital · Updated on 2024-06-13

40

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying children with cystic fibrosis CF to see how probiotic supplements might improve their gut-related quality of life. The study also explores how probiotics and a new CF treatment called elexacaftor-tezacaftor-ivacaftor ETI affect gut bacteria and intestinal inflammation. This research aims to enhance quality of life and reduce gastrointestinal problems in pediatric CF patients. The project includes two parts an observational study and a randomized placebo-controlled trial. In the trial, children aged 3 to 18 years will be randomly assigned to receive either a multi-strain probiotic or a placebo maltodextrin daily for six months. The study will compare changes in gut health and inflammation before and after starting the ETI treatment and probiotic supplementation. Participants will provide stool samples and complete quality of life questionnaires during routine visits before and after treatment. Researchers will monitor gastrointestinal quality of life using the PedsQL GI questionnaire, analyze changes in gut microbiota and intestinal inflammation, and examine body composition linked to lung function. The study is expected to last from the start of probiotic or placebo treatment through six months of follow-up.

CONDITIONS

Brief Title

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here